PMC:7499584 / 12941-13601 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7499584","sourcedb":"PMC","sourceid":"7499584","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7499584","text":"It seems a reasonable approach that interfering with host glycosylation systems hijacked by SARS COV2, plus interfering with the ACE2 receptor glycosylation may combine to 1) interdict infectivity and 2) glycosylation interference with Sialyl LeX can inhibit E-selectin-based inflammatory responses, mitigating the Covid19 ARDS pathology. Important here is that decoys of glycosylation address the host enzyme systems; therefore, the virus cannot perform a simple mutation to overcome the interdiction, as in vaccines, like influenza. In addition, several of the compounds are FDA approved for other indications, which could be repurposed and tested off-label.","tracks":[]}